HRCM
IOVA icon

Hood River Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Hood River Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,216,040
Closed -$30.7M – 162
2025
Q1 		$30.7M Buy
9,216,040
+224,467
+2% +$1.16M 0.52% 75
2024
Q4 		$66.5M Buy
8,991,573
+846,936
+10% +$7.85M 0.98% 38
2024
Q3 		$76.5M Buy
8,144,637
+5,412,210
+198% +$51.3M 1.23% 29
2024
Q2 		$21.9M Buy
2,732,427
+108,189
+4% +$1.16M 0.45% 79
2024
Q1 		$38.9M Buy
2,624,238
+622,728
+31% +$7.25M 0.87% 45
2023
Q4 		$16.3M Buy
2,001,510
+9,175
+0.5% +$48K 0.45% 77
2023
Q3 		$9.07M Buy
1,992,335
+16,784
+0.8% +$110K 0.29% 84
2023
Q2 		$13.9M Buy
+1,975,551
New +$14.1M 0.41% 74
2021
Q2 		– Sell
-460,679
Closed -$14.6M – 121
2021
Q1 		$14.6M Sell
460,679
-44,732
-9% -$1.85M 0.47% 80
2020
Q4 		$23.5M Buy
505,411
+8,546
+2% +$339K 0.78% 57
2020
Q3 		$16.4M Sell
496,865
-50,447
-9% -$1.55M 0.71% 55
2020
Q2 		$15M Buy
+547,312
New +$18M 0.67% 60

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Hood River Capital Management's IOVA Position: Q2 2025 in Review

Hood River Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 9,216,040 shares — an estimated $30.7M sold.

Hood River Capital Management first reported a position in IOVA in Q2 2020 and held it in 12 quarters. The position peaked at $76.5M in Q3 2024. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Hood River Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Hood River Capital Management sold 9,216,040 Iovance Biotherapeutics shares in Q2 2025, an estimated $30.7M.
  • Hood River Capital Management first reported a position in Iovance Biotherapeutics in Q2 2020 and held it in 12 quarters.
  • Hood River Capital Management's Iovance Biotherapeutics position peaked at $76.5M in Q3 2024.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Hood River Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.